Other
T1D
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
T1D is an early-stage landscape with 0 programs across 1 company. The most active players are Entero Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Terminated2 · 50%
Not yet recruiting1 · 25%
Withdrawn1 · 25%
Clinical Trials
Trial Activity
STOP-T1D Low-Dose (ATG)
Terminated·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04291703·2 enrolled
SGLT2i, Pioglitazone, and Ketone Production in T1D
Not yet recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT07056699·24 enrolled
Low-dose IL-2 in Established T1D - The "PROREG" Study
Withdrawn·—·Phase 1/2·NCT03243058
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)